US patent office rejects Pfizer plea on Lipitor to give Ranbaxy shot in the arm
US patent office rejects Pfizer plea on Lipitor to give Ranbaxy shot in the arm
After consecutive litigation losses against Pfizer in its bid to grab a market share of the world's largest selling drug, Lipitor, Ranbaxy can now breathe easy. Last week, the Indian company got a shot in the arm, with the US Patent and Trademark Office (USPTO) issuing a a preliminary rejection of Pfizer's request for reissue of a patent for Lipitor. The verdict gives Ranbaxy hope to launch the cholesterol lowering drug Lipitor as early as March 2010.
Publication Date:
29/04/2008